Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?

McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P.

Clin Genitourin Cancer. 2019 Aug 5. pii: S1558-7673(19)30244-7. doi: 10.1016/j.clgc.2019.07.016. [Epub ahead of print]

PMID:
31594737
2.

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30010-0. doi: 10.1016/j.euo.2019.01.009. [Epub ahead of print]

PMID:
31411963
3.

Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level.

Moussa H, Nguile-Makao M, Robitaille K, Guertin MH, Allaire J, Pelletier JF, Moreel X, Gevariya N, Diorio C, Desmeules P, Têtu B, Lamarche B, Julien P, Fradet V.

Nutrients. 2019 Jul 16;11(7). pii: E1616. doi: 10.3390/nu11071616.

4.

Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series.

Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M.

Urol Oncol. 2019 May;37(5):300.e9-300.e15. doi: 10.1016/j.urolonc.2019.01.017. Epub 2019 Mar 12.

PMID:
30871997
5.

Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice.

Gevariya N, Besançon M, Robitaille K, Picard V, Diabaté L, Alesawi A, Julien P, Fradet Y, Bergeron A, Fradet V.

Prostate. 2019 Jan;79(1):9-20. doi: 10.1002/pros.23706. Epub 2018 Aug 2.

PMID:
30073695
6.

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F.

Eur Urol Focus. 2018 Mar 30. pii: S2405-4569(18)30086-5. doi: 10.1016/j.euf.2018.03.008. [Epub ahead of print]

PMID:
29609897
7.

Urology residents on call: Investigating the workload and relevance of calls.

Thériault B, Marceau-Grimard M, Blais AS, Fradet V, Moore K, Cloutier J.

Can Urol Assoc J. 2018 Feb;12(2):E71-E75. doi: 10.5489/cuaj.4333. Epub 2017 Dec 1.

9.

Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population.

Vigneault É, Savard J, Savard MH, Ivers H, Després P, Foster W, Martin AG, Fradet V.

Can Urol Assoc J. 2017 Dec;11(12):404-410. doi: 10.5489/cuaj.4428. Epub 2017 Nov 1.

10.

Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review.

Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V.

Can Urol Assoc J. 2017 Dec;11(12):419-424. doi: 10.5489/cuaj.4471. Epub 2017 Nov 1. Review.

11.

Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study.

Allaire J, Léger C, Ben-Zvi T, Nguilé-Makao M, Fradet Y, Lacombe L, Fradet V.

Nutr Cancer. 2017 Nov-Dec;69(8):1196-1204. doi: 10.1080/01635581.2017.1367941. Epub 2017 Oct 30.

PMID:
29083243
12.

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.

Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y.

BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25.

13.

Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.

Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F.

Eur Urol Focus. 2017 Dec;3(6):639-642. doi: 10.1016/j.euf.2017.02.007. Epub 2017 Feb 23.

14.

Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients.

Gagné-Loranger M, Lacombe L, Pouliot F, Fradet V, Dagenais F.

Eur J Cardiothorac Surg. 2016 Aug;50(2):317-21. doi: 10.1093/ejcts/ezw023. Epub 2016 Mar 25.

PMID:
27016196
15.

Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification.

Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B, Pavlovich CP.

J Urol. 2016 Aug;196(2):562-9. doi: 10.1016/j.juro.2015.12.093. Epub 2016 Jan 12.

PMID:
26791931
16.

Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis.

Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):307-14. doi: 10.5489/cuaj.2707.

17.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.

Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8.

18.

Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.

Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, Fradet V, Turgeon AF.

JAMA Oncol. 2015 Dec;1(9):1261-9. doi: 10.1001/jamaoncol.2015.2895. Review.

PMID:
26378418
19.

Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.

Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V.

Diagn Pathol. 2015 Jun 13;10:67. doi: 10.1186/s13000-015-0294-0.

20.

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.

Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F.

Cancer Imaging. 2015 Mar 3;15:2. doi: 10.1186/s40644-015-0038-0.

21.

Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer.

Allaire J, Moreel X, Labonté MÈ, Léger C, Caron A, Julien P, Lamarche B, Fradet V.

Eur J Clin Nutr. 2015 Sep;69(9):1004-8. doi: 10.1038/ejcn.2015.7. Epub 2015 Mar 11.

PMID:
25758837
22.

IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness.

Neveu B, Moreel X, Deschênes-Rompré MP, Bergeron A, LaRue H, Ayari C, Fradet Y, Fradet V.

Res Rep Urol. 2014 May 9;6:27-34. doi: 10.2147/RRU.S58643. eCollection 2014.

23.

Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration.

Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, Sheyegan B, Drachenberg D, Cagiannos I, Lacombe L.

Urol Oncol. 2014 Aug;32(6):839-45. doi: 10.1016/j.urolonc.2014.04.006. Epub 2014 May 22.

PMID:
24856978
24.

Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance.

Moreel X, Allaire J, Léger C, Caron A, Labonté MÈ, Lamarche B, Julien P, Desmeules P, Têtu B, Fradet V.

Cancer Prev Res (Phila). 2014 Jul;7(7):766-76. doi: 10.1158/1940-6207.CAPR-13-0349. Epub 2014 May 13.

25.

Diagnostic performance of ultrasound for macroscopic hematuria in the era of multidetector computed tomography urography.

Rhéaume-Lanoie J, Lepanto L, Fradet V, Billiard JS, Tang A.

Can Assoc Radiol J. 2014 Aug;65(3):253-9. doi: 10.1016/j.carj.2013.08.001. Epub 2013 Dec 7.

26.

High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.

Ayari C, LaRue H, Hovington H, Caron A, Bergeron A, Têtu B, Fradet V, Fradet Y.

Hum Pathol. 2013 Aug;44(8):1630-7. doi: 10.1016/j.humpath.2013.01.014. Epub 2013 Apr 8.

PMID:
23574787
28.

The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.

Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y.

Eur Urol. 2013 Jul;64(1):19-25. doi: 10.1016/j.eururo.2012.08.002. Epub 2012 Aug 10.

PMID:
22901983
29.

Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies.

Trudel D, Labbé DP, Bairati I, Fradet V, Bazinet L, Têtu B.

Gynecol Oncol. 2012 Sep;126(3):491-8. doi: 10.1016/j.ygyno.2012.04.048. Epub 2012 May 4. Review.

PMID:
22564714
30.

The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.

Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É.

Eur Urol. 2012 Jul;62(1):88-96. doi: 10.1016/j.eururo.2011.12.021. Epub 2011 Dec 21.

PMID:
22209174
31.

Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment.

Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR.

J Urol. 2011 Dec;186(6):2228-32. doi: 10.1016/j.juro.2011.07.119. Epub 2011 Oct 19.

PMID:
22014796
32.

Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers.

Mauermann J, Pouliot F, Fradet V.

World Rev Nutr Diet. 2011;102:156-171. doi: 10.1159/000327805. Epub 2011 Aug 5. Review. No abstract available.

PMID:
21865830
33.

SRD5A polymorphisms and biochemical failure after radical prostatectomy.

Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E.

Eur Urol. 2011 Dec;60(6):1226-34. doi: 10.1016/j.eururo.2011.06.020. Epub 2011 Jun 29.

PMID:
21715084
34.

Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.

Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR.

Radiology. 2010 Jul;256(1):176-83. doi: 10.1148/radiol.10091147. Epub 2010 May 26.

35.

Urologist density and county-level urologic cancer mortality.

Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR.

J Clin Oncol. 2010 May 20;28(15):2499-504. doi: 10.1200/JCO.2009.26.9597. Epub 2010 Apr 20.

36.

Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer.

Reese AC, Fradet V, Witte JS.

J Nutrigenet Nutrigenomics. 2009;2(3):149-58. doi: 10.1159/000235565. Epub 2009 Sep 23. Review.

37.

Penile sonographic and clinical characteristics in men with Peyronie's disease.

Smith JF, Brant WO, Fradet V, Shindel AW, Vittinghoff E, Chi T, Huang YC, Davis CB, Conti S, Lue TF.

J Sex Med. 2009 Oct;6(10):2858-67. doi: 10.1111/j.1743-6109.2009.01438.x. Epub 2009 Aug 28.

PMID:
19732312
38.

Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.

Fradet V, Cheng I, Casey G, Witte JS.

Clin Cancer Res. 2009 Apr 1;15(7):2559-66. doi: 10.1158/1078-0432.CCR-08-2503. Epub 2009 Mar 24.

39.

Pathological outcomes of candidates for active surveillance of prostate cancer.

Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR.

J Urol. 2009 Apr;181(4):1628-33; discussion 1633-4. doi: 10.1016/j.juro.2008.11.107. Epub 2009 Feb 23.

PMID:
19233388
40.

Prospective assessment of malnutrition in urologic patients.

Karl A, Rittler P, Buchner A, Fradet V, Speer R, Walther S, Stief GC.

Urology. 2009 May;73(5):1072-6. doi: 10.1016/j.urology.2008.12.037. Epub 2009 Feb 20.

PMID:
19232689
41.

Is the complication rate of radical cystectomy predictive of the complication rate of other urological procedures?

Fradet V, Allareddy V, Aaronson DS, Konety BR.

J Urol. 2009 Mar;181(3):1054-9; discussion 1059-60. doi: 10.1016/j.juro.2008.11.016. Epub 2009 Jan 16.

PMID:
19150541
42.

Geographic distribution of urologists throughout the United States using a county level approach.

Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR.

J Urol. 2009 Feb;181(2):760-5; discussion 765-6. doi: 10.1016/j.juro.2008.10.034. Epub 2008 Dec 16.

43.

Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer.

Fradet V, Gaudreau C, Perrotte P, Côté J, Paquin JM.

Can Urol Assoc J. 2007 Sep;1(3):269-72.

44.

Re: results from three municipal hospitals regarding radical cystectomy on elderly patients.

Fradet V, Konety BR.

Int Braz J Urol. 2008 Jan-Feb;34(1):97-8. No abstract available.

45.

A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome.

Fradet V, Konety BR.

BJU Int. 2008 Jan;101(2):257-8; author reply 258-9. doi: 10.1111/j.1464-410X.2007.07394_2.x. No abstract available.

46.

The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.

Chun FK, Briganti A, Lebeau T, Fradet V, Steuber T, Walz J, Schlomm T, Eichelberg C, Haese A, Erbersdobler A, McCormack M, Perrotte P, Graefen M, Huland H, Karakiewicz PI.

Eur Urol. 2006 Feb;49(2):273-8; discussion 278-9. Epub 2006 Jan 6.

PMID:
16413103
47.

An epidural abscess following transrectal ultrasound-guided biopsies of the prostate.

Fradet V, McCormack M, Perrotte P, Karakiewicz P, Saad F.

Can J Urol. 2005 Dec;12(6):2899-900.

PMID:
16401377
48.

Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.

Fradet V, Lessard L, Bégin LR, Karakiewicz P, Masson AM, Saad F.

Clin Cancer Res. 2004 Dec 15;10(24):8460-4.

49.

Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression.

Cardinal H, Barama AA, Fradet V, Lallier M, Lévesque R, St Louis G, Hébert MJ, Girardin C, Pâquet M, Daloze P.

Transplant Proc. 2004 Mar;36(2 Suppl):448S-450S.

PMID:
15041384

Supplemental Content

Loading ...
Support Center